Development Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection 75A50125C00018
Summary
AI-generated · Oct 08, 2025Development of a concentrated Tranexamic Acid (TXA) for intramuscular injection to support FDA approval, with a formulation that can be delivered in a prefilled syringe or a dedicated autoinjector.
This effort is a competitive cost-share contract under FAR 35.006(c) due to imprecise specifications and difficulties in accurate cost estimation. Awarded to Rafa Laboratories Ltd for $186,004,780.
This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection. The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector. This contract action was awarded competitively as a Cost Share Contract. A Cost Share Contract was used in accordance with FAR 35.006 (c) due to an absence of precise specifications and difficulties in estimating costs with accuracy.
From Award Notice posted on Oct 01, 2025Notice history
1-
Award Notice LATEST Posted Oct 01, 2025
Details
Award Information
Award Notices
Posted: Oct 01, 2025
This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection. The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector. This contract...
Awardees
| Company Name | UEI | CAGE Code | Location |
|---|---|---|---|
| RAFA LABORATORIES LTD | CKDNTKNDPMJ6 | 0905A | Jerusalem |
Contacts
Agency
Place of Performance
ISR